A Study of ZT002 Injection in Participants With Overweight or Obesity
Status:
ENROLLING_BY_INVITATION
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
This study will comprise a randomized, double-blind, placebo-controlled, multiple-ascending-dose, safety, tolerability, and pharmacokinetics study of ZT002 in participants with Overweight or Obesity.